The US Food and Drug Administration has approved Abbott's Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. It is indicated for patients with mitral valve disease caused by ...

Novartis launched a tender offer for Regulus Therapeutics. Biogen and City Therapeutics announced a partnership to develop a drug for an undisclosed central nervous system disease. Eli Lilly bought ...

Abbott Laboratories recently received FDA clearance for Tendyne, its transcatheter mitral valve replacement system. The news comes on the heels of Edwards Lifesciences Corp. securing a CE mark for its ...

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Abbott Laboratories on May 27 and set a price target of $145.00. The company’s shares closed last Wednesday at $132.02. According to ...

Bonus Oct 21, 2022 Oct 24, 2022 Sep 05, 2022 Bonus Ratio: 1 share(s) for every 1 shares held ...

The company has so far treated patients who were weeks or months away from a transplant, but the device is theoretically suitable for longer-term use. After a three-year IPO drought, the industry is ...

Objectives Exercise-based cardiac rehabilitation (CR) may be beneficial to patients following transcatheter aortic valve implantation (TAVI) and open surgical aortic valve replacement (SAVR). We aimed ...